|
1
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haffty BG, Yang Q, Reiss M, Kearney T,
Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16 (Suppl
1):S1–S11. 2011. View Article : Google Scholar
|
|
8
|
Chang-Qing Y, Jie L, Shi-Qi Z, Kun Z,
Zi-Qian G, Ran X, Hui-Meng L, Ren-Bin Z, Gang Z, Da-Chuan Y and
Chen-Yan Z: Recent treatment progress of triple negative breast
cancer. Prog Biophys Mol Biol. Nov 21–2019.(Epub ahead of print).
PubMed/NCBI
|
|
9
|
Troyer KL and Lee DC: Regulation of mouse
mammary gland development and tumorigenesis by the ERBB signaling
network. J Mammary Gland Biol Neoplasia. 6:7–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar R and Wang RA: Protein kinases in
mammary gland development and cancer. Microsc Res Tech. 59:49–57.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corkery B, Crown J, Clynes M and O'Donovan
N: Epidermal growth factor receptor as a potential therapeutic
target in triple-negative breast cancer. Ann Oncol. 20:862–867.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ,
Kim YJ, Kim JH, Kang E, Kim SW, Kim IA and Park SY: High EGFR gene
copy number predicts poor outcome in triple-negative breast cancer.
Mod Pathol. 27:1212–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Masuda H, Zhang D, Bartholomeusz C,
Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth
factor receptor in breast cancer. Breast Cancer Res Treat.
136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gelmon K, Dent R, Mackey JR, Laing K,
McLeod D and Verma S: Targeting triple-negative breast cancer:
Optimising therapeutic outcomes. Ann Oncol. 23:2223–2234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakai K, Hung MC and Yamaguchi H: A
perspective on anti-EGFR therapies targeting triple-negative breast
cancer. Am J Cancer Res. 6:1609–1623. 2016.PubMed/NCBI
|
|
17
|
Wang Z, Zhang X, Shen P, Loggie BW, Chang
Y and Deuel TF: Identification, cloning, and expression of human
estrogen receptor-alpha36, a novel variant of human estrogen
receptor-alpha66. Biochem Biophys Res Commun. 336:1023–1027. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee LM, Cao J, Deng H, Chen P, Gatalica Z
and Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed
in ER-positive and -negative human breast carcinomas. Anticancer
Res. 28:479–483. 2008.PubMed/NCBI
|
|
19
|
Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J,
Wang T, Fan Z, Fan T, Lin B, et al: Expression of ER-{alpha}36, a
novel variant of estrogen receptor {alpha}, and resistance to
tamoxifen treatment in breast cancer. J Clin Oncol. 27:3423–3429.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang ZY and Yin L: Estrogen receptor
alpha-36 (ER-α36): A new player in human breast cancer. Mol Cell
Endocrinol. 418:193–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Zhang X, Shen P, Loggie BW, Chang
Y and Deuel TF: A variant of estrogen receptor-{alpha},
hER-{alpha}36: Transduction of estrogen- and antiestrogen-dependent
membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA.
103:9063–9068. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang XJ, Xi YM and Li ZJ: Icaritin: A
novel natural candidate for hematological malignancies therapy.
Biomed Res Int. 2019:48602682019.PubMed/NCBI
|
|
23
|
Hong J, Zhang Z, Lv W, Zhang M, Chen C,
Yang S, Li S, Zhang L, Han D and Zhang W: Icaritin synergistically
enhances the radiosensitivity of 4T1 breast cancer cells. PLoS One.
8:e713472013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Priceman SJ, Xin H, Zhang W, Deng J,
Liu Y, Huang J, Zhu W, Chen M, Hu W, et al: Icaritin inhibits
JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One.
8:e816572013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu JF, Li ZJ, Zhang GS, Meng K, Kuang WY,
Li J, Zhou XF, Li RJ, Peng HL, Dai CW, et al: Icaritin shows potent
anti-leukemia activity on chronic myeloid leukemia in vitro and in
vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS
One. 6:e237202011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Zheng N, Dong J, Liu L and Huang
J: Estrogen receptor-α36 is involved in icaritin induced growth
inhibition of triple-negative breast cancer cells. J Steroid
Biochem Mol Biol. 171:318–327. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brinkley BR, Beall PT, Wible LJ, Mace ML,
Turner DS and Cailleau RM: Variations in cell form and cytoskeleton
in human breast carcinoma cells in vitro. Cancer Res. 40:3118–3129.
1980.PubMed/NCBI
|
|
28
|
Cailleau R, Young R, Olive M and Reeves WJ
Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer
Inst. 53:661–674. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chavez KJ, Garimella SV and Lipkowitz S:
Triple negative breast cancer cell lines: One tool in the search
for better treatment of triple negative breast cancer. Breast Dis.
32:35–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang L and Wang ZY: Breast cancer cell
growth inhibition by phenethyl isothiocyanate is associated with
down-regulation of oestrogen receptor-alpha36. J Cell Mol Med.
14:1485–1493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Normanno N, De Luca A, Bianco C, Strizzi
L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and
Salomon DS: Epidermal growth factor receptor (EGFR) signaling in
cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu D, He J, Yuan Z, Wang S, Peng R, Shi
Y, Teng X and Qin T: EGFR expression correlates with decreased
disease-free survival in triple-negative breast cancer: A
retrospective analysis based on a tissue microarray. Med Oncol.
29:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Ding L, Kang L and Wang ZY:
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen
signaling in ER-negative breast cancer cells. PLoS One.
7:e301742012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang XT, Ding L, Kang LG and Wang ZY:
Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen
signaling of ER-negative breast cancer cells. Oncol Rep.
27:2057–2065. 2012.PubMed/NCBI
|
|
38
|
Tsai EM, Wang SC, Lee JN and Hung MC: Akt
activation by estrogen in estrogen receptor-negative breast cancer
cells. Cancer Res. 61:8390–8392. 2001.PubMed/NCBI
|
|
39
|
Friedl A and Jordan VC: Oestradiol
stimulates growth of oestrogen receptor-negative MDA-MB-231 breast
cancer cells in immunodeficient mice by reducing cell loss. Eur J
Cancer. 30A:1559–1564. 1994. View Article : Google Scholar : PubMed/NCBI
|
